Welcome to our dedicated page for CEMTREX SEC filings (Ticker: CETX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CEMTREX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CEMTREX's regulatory disclosures and financial reporting.
Cemtrex Inc. is implementing a 1-for-15 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 29, 2025. The stock will begin trading on a split-adjusted basis that day under the same trading symbol, CETX, with a new CUSIP number 15130G873.
As of this filing, Cemtrex has 11,084,809 shares of common stock outstanding, which will be reduced to roughly one-fifteenth of that amount after the split, subject to rounding of fractional shares. The reverse split was approved earlier by stockholders and is intended to help the company regain compliance with Nasdaq’s minimum $1.00 bid price requirement.
Most options, warrants, and equity awards will be proportionately adjusted so that holders keep essentially the same aggregate exercise price. However, Cemtrex discloses that its Adjustable Warrants, currently exercisable for 15,412,956 shares at an exercise price of $0.5737 per share, contain provisions that will reduce the post-split exercise price and significantly increase the number of underlying shares, while keeping the total exercise price the same.
Cemtrex Inc. reported that its board of directors approved payment of the upcoming dividend on its Series 1 Preferred Stock in additional shares of the same Series 1 Preferred Stock rather than in cash. The new shares are expected to be issued on October 7, 2025 to holders of record as of the close of business on September 30, 2025.
Holders of the Series 1 Preferred Stock are entitled to receive dividends at a 10% annual rate, based on a $10.00 per share preference amount, with dividends payable on a semiannual schedule.
CEMTREX Inc. is the subject of a jointly filed Schedule 13G/A by three Altium-related reporting persons that discloses no reportable stake in the company’s common stock. The filing names Altium Healthcare Long Short Onshore Fund LP, Altium Capital Management LLC and Altium Healthcare Long Short GP LLC and states the Fund as the record and direct beneficial owner of the securities covered by the statement while simultaneously reporting an aggregate beneficial ownership of 0 shares (0% of the class). The filers note they may be deemed members of a group for regulatory purposes but expressly state the filing is not an admission of beneficial ownership or of acting to acquire or influence control. The statement also includes a certification that the securities were not acquired to influence control.
This Schedule 13G/A discloses that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the Reporting Persons) are each deemed to beneficially own 336,801 shares of Cemtrex Inc. common stock, representing approximately 9.99% of the company’s outstanding common stock as presented in the filing. The shares reported are issuable upon exercise of a warrant held by Intracoastal (Intracoastal Warrant 1).
Each Reporting Person has shared voting and shared dispositive power over 336,801 shares and no sole voting or dispositive power. The filing explains that blocker provisions in Intracoastal Warrant 1 and Intracoastal Warrant 2 prevent exercise to the extent doing so would increase ownership above 9.99% and 4.99%, respectively, thereby excluding 1,671,598 and 142,778 warrant shares from current beneficial ownership calculations. Without those blocker provisions, the Reporting Persons may be deemed to beneficially own 2,151,177 shares.